3rd Bioequivalence Summit

Every new formulation and generic drug needs to demonstrate bioequivalence to secure market approval. But each of these required tests can be complicated by innovations in drug delivery or dosing features, yielding unpredictable challenges if companies modify delivery techniques to try to improve bioavailability.

The 3rd Bioequivalence Summit is your must-attend event for achieving true interchangeability of both small molecule generics and biosimilars across multiple delivery platforms. No other conference goes into as much depth of scientific detail in order to help broaden the robustness and market uptake of your generic and biosimilar portfolio.

Top Five Reasons to Attend

1. Analysis of the latest regulatory guidelines on bioequivalence
2. Detailed review of improvements to bioequivalence testing protocols
3. Success strategies for bioequivalence testing across multiple drug delivery methods, including oral, topical, transdermal, sublingual and inhaled
4. Insight on consumer and physician perceptions of generic drugs
5. A way forward for improving the performance, regulatory approval and market uptake for biosimilars

Who Should Attend

This conference is specifically designed for biotech and pharma professionals responsible for:

This conference is also of interest to: